Tempest Therapeutics, Inc. develops clinical-stage cell therapy and small-molecule product candidates for cancer and related disease areas. News about TPST centers on its dual-targeting CAR-T platform, including TPST-2003, a CD19/BCMA CAR-T therapy under development for relapsed or refractory multiple myeloma, and clinical updates from programs such as REDEEM-1 and POEMS-1.
Company updates also cover CAR-T manufacturing and technology-transfer work, partner-supported development activities, business development and licensing priorities, and the amezalpat small-molecule program. Recurring corporate news includes financial results, pipeline portfolio changes following acquired CAR-T assets, leadership appointments, and governance or capital-structure matters tied to the company’s Nasdaq-listed common stock.
Summary not available.
Summary not available.
Tempest Therapeutics (Nasdaq: TPST) announced the acceptance of an abstract for the 2023 ASCO Annual Meeting, scheduled for June 2-6, 2023, in Chicago. The abstract focuses on TPST-1495, an EP2/EP4 prostaglandin receptor dual antagonist.
Presentation Details:
- Title: A Phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors
- Session Title: Developmental Therapeutics — Molecularly Targeted Agents and Tumor Biology
- Session Date and Time: June 3, 2023; 8:00 a.m. – 11:00 a.m. ET
- Abstract Number: 3107
The abstract will be released on May 25, 2023, at 5:00 p.m. ET on the ASCO website.
Tempest Therapeutics, Inc. (Nasdaq: TPST) recently presented new data from its TPST-1120 and TREX1 programs at the 2023 American Association for Cancer Research Annual Meeting. The findings from TPST-1120, an oral PPAR⍺ antagonist, highlighted biomarker changes linked to drug exposure and response levels in patients undergoing treatment in a Phase 1 trial. Additionally, the TREX1 inhibitor program showcased novel human TREX1 enzyme structures, paving the way for potent inhibitors targeting the STING pathway. The company aims to advance TPST-1120 through multiple oncology indications and initiate human trials for the TREX1 inhibitors. Initial results from ongoing trials are expected soon, indicating promising possibilities for future cancer therapies.
Tempest Therapeutics, Inc. (TPST) reported significant clinical progress in 2022, highlighted by the completion of a Phase 1 study for TPST-1120, indicating a 30% objective response rate in patients unresponsive to traditional therapies. The randomization study in collaboration with Roche for first-line hepatocellular carcinoma (HCC) patients is fully enrolled, with data expected in mid-2023. Financially, Tempest saw a decline in cash reserves to $31.2 million and a net loss of $35.7 million for the year. However, the company anticipates adequate funding through Q2 2024, with ongoing developments in TPST-1495 and a promising TREX1 inhibitor program.
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced a poster presentation by Dr. Nathan Standifer at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Meeting from March 15-17 in Denver, CO, and online. The presentation will detail biomarker findings from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist. Key data indicate a link between clinical benefits and changes in fatty acid oxidation and gene expression. The presentation is scheduled for March 16, 2023, from 6:00 to 7:30 p.m. MT, and carries the abstract number 78. Tempest Therapeutics is focused on developing innovative oncology therapeutics that target various tumors.
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced two abstracts accepted for presentation at the 2023 AACR Annual Meeting, scheduled for April 14-19 in Orlando, FL. The posters will cover biomarker data from the Phase 1 trial of TPST-1120, an oral selective PPAR⍺ antagonist, and preclinical data on the TREX1 inhibitor targeting the STING pathway. The first presentation, focusing on lipid and immune-based biomarkers, will occur on April 17, 2023. The second will discuss novel TREX1 inhibitors also on April 17. Tempest's innovative therapies are designed to treat various tumors through immune-mediated mechanisms, pending FDA approval.
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology firm, will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 11:30 am ET. The discussion will address their innovative therapeutic approaches combining targeted and immune-mediated mechanisms for cancer treatment. Key programs include TPST-1120 and TPST-1495, which are in clinical trials aimed at enhancing cancer therapies. Interested parties can access the live or archived chat via the investor section of Tempest's website.
Tempest Therapeutics (Nasdaq: TPST) presented new data on TPST-1120 and TPST-1495 at the SITC Annual Meeting in Boston (Nov 10-12, 2022). TPST-1120, a PPAR-α antagonist, showed promising pharmacodynamic changes in patients who benefited from treatment. Meanwhile, TPST-1495 demonstrated superior immune activation compared to single inhibitors and reduced tumor size in preclinical models. The findings suggest potential biomarkers for patient selection in future studies, strengthening the company's position in oncology therapeutics.
Tempest Therapeutics, Inc. (Nasdaq: TPST) reported its Q3 2022 financial results, highlighting a net loss of $8.9 million or $0.66 per share, compared to a net loss of $8.1 million or $1.21 per share in Q3 2021. The company ended the quarter with $42.8 million in cash, down from $51.8 million at year-end 2021. Research and development expenses increased to $6.0 million, driven by expanded efforts. Tempest continues enrollment in clinical trials for its products TPST-1120 and TPST-1495, with key data presentations expected at the upcoming SITC annual meeting.